Dr. Reddy’s Laboratories: Ambitious ESG Goals

Dr. Reddy’s Laboratories is committed to becoming carbon neutral in direct operations as well as reducing indirect carbon emissions by 2030

Dr Reddy’s Completes Phase I Study Of Biosimilar Of Tocilizumab

Dr Reddy’s Laboratories, a global pharmaceutical company, said that its tocilizumab biosimilar candidate, DRL_TC, successfully met its primary and secondary endpoints in Phase I clinical study, the company said in an exchange filing on Monday

Lupin, Glenmark, Dr Reddy's Recall Products In US

According to industry estimates, the US generic drug market was estimated to be around USD 115.2 billion in 2019

Mankind Pharma To Acquire Combihale And Daffy Brands From Dr Reddy's Laboratories

The acquisition of the product is expected to strengthen the company's presence in the inhalation respiratory market segment, Mankind Pharma said in a statement

Sputnik V Pilot In Final Leg: Scaled Up To Other Cities-Dr Reddy S

Dr Reddys Laboratories is in a pact with Russian Direct Investment Fund to sell the first 125 million people doses (250 million vials) of SputnikVin India.

Dr Reddys Labs Launches Tecfidera Generic In US Market

The company's product is a therapeutic equivalent generic version of Biogen's Tecfidera delayed-release capsules, the Hyderabad-based drug firm said in a statement.

Merck Moves US Court Against Dr Reddy's On Diabetic Drugs

Merck has filed the possible patent infringement petition against Dr Reddy's in the United States District Court for the District of Delaware on four counts.

New Drugs For Paediatrics, Dermatology, Oncology On The Anvil

The revenues from the proprietary products segment were Rs 795 crorefor the year-ended March 31, 2020, an increase of 67 per cent as compared to Rs 475 crore with the corresponding period previous year

Dr Reddy's Posts Q3 Net Profit On Strong India, US Sales

Despite challenging market conditions in most of its emerging markets and a 21 per cent sales drop in Russia, the company's net profit at Rs 579.2 crore for the quarter grew marginally compared to the year-ago quarter

DRL, Fujifilm End Generic Drugs JV

So Near, Yet So Far

Dr Reddy's Q1 Jumps 28%, Slightly Lags Estimates

DLF Treads Lower After Exclusion News

Dr Reddy's Gets US Nod For Osteoporosis Drug

Dr Reddy's N. America Sales Offset Charge In Q4